Amgen Outpaces Regeneron With 26.9% Rally and Technical Strength
Amgen shares have risen 26.9% over the past 52 weeks and 18.6% year to date, outperforming Regeneron’s 11.2% 52-week gain and 1.3% YTD increase. The stock has traded above its 50-day moving average since July 2025 and above its 200-day moving average since October, reflecting sustained investor confidence.
1. Amgen’s Relative Performance
Amgen’s shares rose 26.9% over the past 52 weeks and 18.6% year to date, surpassing Regeneron’s 11.2% 52-week gain and 1.3% YTD increase, highlighting stronger investor appetite for its products.
2. Technical Momentum and Support
The stock has traded above its 50-day moving average since mid-July 2025 and above its 200-day moving average since late October 2025, signaling sustained upward momentum and robust technical support.
Related News
NVDA
Nvidia Raises July Quarter Guidance, Forecasts $91B Fiscal 2027 Revenue
NVDA•
NVDA
Nvidia Projects $20 Billion in CPU Sales Within $200 Billion Market
NVDA•
INTU
Intuit Beats Q3 Estimates, Cuts 17% Workforce and Raises Guidance
INTU•
EXOD
Exodus Movement April XO Swap Volume Up 44% to $98M, Global Pay Launch
EXOD•
VBCF
Vanguard’s BondBuilder ETFs Garner $242M, Join $70B Target Maturity Market
VBCF•
Sources
FF